Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2.
COVID-19
Cytokine storm
Melatonin
Omicron variant
REGN-COV2
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
20
02
2022
accepted:
23
03
2022
pubmed:
8
4
2022
medline:
10
6
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
The omicron variant (B.529) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in late 2021, caused panic worldwide due to its contagiousness and multiple mutations in the spike protein compared to the Delta variant (B.617.2). There is currently no specific antiviral available to treat Coronavirus disease 2019 (COVID-19). However, studies on neutralizing monoclonal antibodies (mAb) developed to fight COVID-19 are growing and gaining traction. REGN-COV2 (Regeneron or imdevimab-casirivimab combination), which has been shown in recent studies to be less affected by Omicron's RBD (receptor binding domain) mutations among other mAb cocktails, plays an important role in adjuvant therapy against COVID-19. On the other hand, it is known that melatonin, which has antioxidant and immunomodulatory effects, can prevent a possible cytokine storm, and other severe symptoms that may develop in the event of viral invasion. Along with all these findings, we believe it is crucial to evaluate the use of melatonin with REGN-COV2, a cocktail of mAbs, as an adjuvant in the treatment and prevention of COVID-19, particularly in immunocompromised and elderly patients.
Identifiants
pubmed: 35389130
doi: 10.1007/s11033-022-07419-9
pii: 10.1007/s11033-022-07419-9
pmc: PMC8986966
doi:
Substances chimiques
Adjuvants, Vaccine
0
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antibodies, Neutralizing
0
Antineoplastic Agents, Immunological
0
Drug Combinations
0
casirivimab and imdevimab drug combination
0
imdevimab
2Z3DQD2JHM
casirivimab
J0FI6WE1QN
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4061-4068Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Parasher A (2021) COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 97:312–320. https://doi.org/10.1136/postgradmedj-2020-138577
doi: 10.1136/postgradmedj-2020-138577
Aleem A, Akbar Samad AB, Slenker AK (2022) Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). StatPearls Publishing, In StatPearls
Wang L, Cheng G (2021) Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. J Med Virol 94:1728–1733
doi: 10.1002/jmv.27516
Kim S, Liu Y, Ziarnik M, Cao Y, Zhang XF, Im W (2022) Binding of Human ACE2 and RBD of Omicron Enhanced by Unique Interaction Patterns Among SARS-CoV-2 Variants of Concern. Preprint. bioRxiv: the preprint server for biology https://doi.org/10.1101/2022.01.24.477633
Lupala CS, Ye Y, Chen H, Su XD, Liu H (2022) Mutations on RBD of SARS-CoV-2 omicron variant result in stronger binding to human ACE2 receptor. Biochem Biophys Res Commun 590:34–41. https://doi.org/10.1016/j.bbrc.2021.12.079
doi: 10.1016/j.bbrc.2021.12.079
Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A et al (2021) SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol 12:701501. https://doi.org/10.3389/fimmu.2021.701501
doi: 10.3389/fimmu.2021.701501
Sekine T, Perez-Potti A, Rivera-Ballesteros O et al (2020) Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183:158-168.e14. https://doi.org/10.1016/j.cell.2020.08.017
doi: 10.1016/j.cell.2020.08.017
Grifoni A, Weiskopf D, Ramirez SI et al (2020) Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181:1489-1501.e15. https://doi.org/10.1016/j.cell.2020.05.015
doi: 10.1016/j.cell.2020.05.015
Fajnzylber J, Regan J, Coxen K et al (2020) SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun 11:5493. https://doi.org/10.1038/s41467-020-19057-5
doi: 10.1038/s41467-020-19057-5
Kreuzberger N, Hirsch C, Chai KL et al (2021) SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013825.pub2
doi: 10.1002/14651858.CD013825.pub2
Liu LD, Lian C, Yeap LS, Meng FL (2020) The development of neutralizing antibodies against SARS-CoV-2 and their common features. J Mol Cell Biol 12:980–986. https://doi.org/10.1093/jmcb/mjaa070
doi: 10.1093/jmcb/mjaa070
Heustess AM, Allard MA, Thompson DK, Fasinu PS (2021) Clinical management of COVID-19: a review of pharmacological treatment options. Pharmaceuticals (Basel) 14:520. https://doi.org/10.3390/ph14060520
doi: 10.3390/ph14060520
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R (2020) The COVID-19 cytokine storm; what we know so far. Front Immunol 11:1446. https://doi.org/10.3389/fimmu.2020.01446
doi: 10.3389/fimmu.2020.01446
Kim JS, Lee JY, Yang JW et al (2021) Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 11:316–329. https://doi.org/10.7150/thno.49713
doi: 10.7150/thno.49713
Zhang R, Wang X, Ni L et al (2020) COVID-19: melatonin as a potential adjuvant treatment. Life Sci 250:117583. https://doi.org/10.1016/j.lfs.2020.117583
doi: 10.1016/j.lfs.2020.117583
Marseglia L, Gitto E, Laschi E et al (2021) Antioxidant effect of melatonin in preterm newborns. Oxid Med Cell Longev 2021:6308255. https://doi.org/10.1155/2021/6308255
doi: 10.1155/2021/6308255
Álvarez-Sánchez N, Cruz-Chamorro I, López-González A et al (2015) Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance. Brain Behav Immun 50:101–114. https://doi.org/10.1016/j.bbi.2015.06.021
doi: 10.1016/j.bbi.2015.06.021
Bahrampour Juybari K, Pourhanifeh MH, Hosseinzadeh A et al (2020) Melatonin potentials against viral infections including COVID-19: current evidence and new findings. Virus Res 287:198108. https://doi.org/10.1016/j.virusres.2020.198108
doi: 10.1016/j.virusres.2020.198108
Wang W, Xu Y, Gao R et al (2020) Detection of SARS-CoV-2 in diferent types of clinical specimens. JAMA 323:1843–1844. https://doi.org/10.1001/jama.2020.3786
doi: 10.1001/jama.2020.3786
Marchi R, Sugita B, Centa A et al (2021) The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review. Infect Genet Evol 91:104832. https://doi.org/10.1016/j.meegid.2021.104832
doi: 10.1016/j.meegid.2021.104832
Wang Z, Schmidt F, Weisblum Y et al (2021) mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592:616–622. https://doi.org/10.1038/s41586-021-03324-6
doi: 10.1038/s41586-021-03324-6
Hansen J, Baum A, Pascal KE et al (2020) Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369:1010–1014. https://doi.org/10.1126/science.abd0827
doi: 10.1126/science.abd0827
Phan AT, Gukasyan J, Arabian S, Wang S, Neeki MM (2021) Emergent inpatient administration of casirivimab and imdevimab antibody cocktail for the treatment of COVID-19 pneumonia. Cureus 13:e15280. https://doi.org/10.7759/cureus.15280
doi: 10.7759/cureus.15280
O’Brien MP, Forleo-Neto E, Musser BJ et al (2021) Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med 385:1184–1195. https://doi.org/10.1056/NEJMoa2109682
doi: 10.1056/NEJMoa2109682
Taylor PC, Adams AC, Hufford MM et al (2021) Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 21:382–393. https://doi.org/10.1038/s41577-021-00542-x
doi: 10.1038/s41577-021-00542-x
Baum A, Ajithdoss D, Copin R et al (2020) REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370:1110–1115. https://doi.org/10.1126/science.abe2402
doi: 10.1126/science.abe2402
Chen J, Wang R, Gilby NB, Wei GW (2022) Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model 62:412–422. https://doi.org/10.1021/acs.jcim.1c01451
doi: 10.1021/acs.jcim.1c01451
Tamimi F, Abusamak M, Akkanti B et al (2020) The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome. Br J Pharmacol 177:4845–4850. https://doi.org/10.1111/bph.15140
doi: 10.1111/bph.15140
Kočar E, Režen T, Rozman D (2021) Cholesterol, lipoproteins, and COVID-19: basic concepts and clinical applications. Biochim Biophys Acta Mol Cell Biol Lipids 1866:158849. https://doi.org/10.1016/j.bbalip.2020.158849
doi: 10.1016/j.bbalip.2020.158849
Schroor MM, Sennels HP, Fahrenkrug J et al (2019) Diurnal variation of markers for cholesterol synthesis, cholesterol absorption, and bile acid synthesis: a systematic review and the bispebjerg study of diurnal variations. Nutrients 11:1439. https://doi.org/10.3390/nu11071439
doi: 10.3390/nu11071439
Giri A, Srinivasan A, Sundar IK (2021) COVID-19: sleep, circadian rhythms and immunity - repurposing drugs and chronotherapeutics for SARS-CoV-2. Front Neurosci 15:674204. https://doi.org/10.3389/fnins.2021.674204
doi: 10.3389/fnins.2021.674204
Borrmann H, McKeating JA, Zhuang X (2021) The circadian clock and viral infections. J Biol Rhythms 36:9–22. https://doi.org/10.1177/0748730420967768
doi: 10.1177/0748730420967768
Sehirli AÖ, Chukwunyere U, Aksoy U, Sayiner S, Abacioglu N (2021) The circadian clock gene Bmal1: role in COVID-19 and periodontitis. Chronobiol Int 38:779–784. https://doi.org/10.1080/07420528.2021.1895198
doi: 10.1080/07420528.2021.1895198
Zhuang X, Tsukuda S, Wrensch F et al (2021) The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. iScience 24:103144
doi: 10.1016/j.isci.2021.103144
Mercan M, Şehirli AÖ, Chukwunyere U, Abacıoğlu N (2021) Acute kidney injury due to COVID-19 and the circadian rhythm. Med Hypotheses 146:110463. https://doi.org/10.1016/j.mehy.2020.110463
doi: 10.1016/j.mehy.2020.110463
Vieira E, Mirizio GG, Barin GR, de Andrade RV et al (2020) Clock genes, inflammation and the immune system-implications for diabetes, obesity and neurodegenerative diseases. Int J Mol Sci 21:9743. https://doi.org/10.3390/ijms21249743
doi: 10.3390/ijms21249743
Grivas TB, Savvidou OD (2007) Melatonin the “light of night” in human biology and adolescent idiopathic scoliosis. Scoliosis 2:6. https://doi.org/10.1186/1748-7161-2-6
doi: 10.1186/1748-7161-2-6
Yang L, Xie X, Tu Z, Fu J et al (2021) The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther 6:255. https://doi.org/10.1038/s41392-021-00679-0
doi: 10.1038/s41392-021-00679-0
Emet M, Ozcan H, Ozel L et al (2016) A review of melatonin, its receptors and drugs. Eurasian J Med 48:135–141. https://doi.org/10.5152/eurasianjmed.2015.0267
doi: 10.5152/eurasianjmed.2015.0267
Sehirli AO, Sayiner S, Serakinci N (2020) Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147). Mol Biol Rep 47:8229–8233. https://doi.org/10.1007/s11033-020-05830-8
doi: 10.1007/s11033-020-05830-8
Perflyeva YV, Ostapchuk YO, Abdolla N et al (2019) Exogenous melatonin up-regulates expression of CD62L by lymphocytes in aged mice under infammatory and non-infammatory conditions. Immunol Invest 48:632–643. https://doi.org/10.1080/08820139.2019.1586918
doi: 10.1080/08820139.2019.1586918
Srinivasan V, Maestroni GJ, Cardinali DP et al (2005) Melatonin, immune function and aging. Immun Ageing 2:17. https://doi.org/10.1186/1742-4933-2-17
doi: 10.1186/1742-4933-2-17
Carrillo-Vico A, Lardone PJ, Álvarez-Śnchez N et al (2013) Melatonin: bufering the immune system. Int J Mol Sci 14:8638–8683. https://doi.org/10.3390/ijms14048638
doi: 10.3390/ijms14048638
Negrette B, Bonilla E, Valero N et al (2001) Melatonin treatment enhances the efciency of mice immunization with venezuelan equine encephalomyelitis virus TC-83. Neurochem Res 26:767–770. https://doi.org/10.1023/a:1011645400123
doi: 10.1023/a:1011645400123
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM et al (2020) SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 54:62–75. https://doi.org/10.1016/j.cytogfr.2020.06.001
doi: 10.1016/j.cytogfr.2020.06.001
Wang K, Chen W, Zhou Y-S et al (2020) SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. https://doi.org/10.1101/2020.03.14.988345
Mahmudpour M, Roozbeh J, Keshavarz M et al (2020) COVID-19 cytokine storm: the anger of inflammation. Cytokine 133:155151. https://doi.org/10.1016/j.cyto.2020.155151
doi: 10.1016/j.cyto.2020.155151
Farias TSM, da de, Paixao RI, Cruz MM, et al (2019) Melatonin supplementation attenuates the pro-inflammatory adipokines expression in visceral fat from obese mice induced by a high-fat diet. Cells 8:1041. https://doi.org/10.3390/cells8091041
doi: 10.3390/cells8091041
Camp OG, Bai D, Gonullu DC, Nayak N, Abu-Soud HM (2021) Melatonin interferes with COVID-19 at several distinct ROS-related steps. J Inorg Biochem 223:111546. https://doi.org/10.1016/j.jinorgbio.2021.111546
doi: 10.1016/j.jinorgbio.2021.111546
Williamson EJ, Walker AJ, Bhaskaran K et al (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature 584:430–436. https://doi.org/10.1038/s41586-020-2521-4
doi: 10.1038/s41586-020-2521-4
Ueland T, Holter JC, Holten AR et al (2021) Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect 81:e41–e43. https://doi.org/10.1016/j.jinf.2020.06.061
doi: 10.1016/j.jinf.2020.06.061
Solun B, Shoenfeld Y (2020) Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. Med Drug Discov 7:100052. https://doi.org/10.1016/j.medidd.2020.100052
doi: 10.1016/j.medidd.2020.100052
Ogino T, Than TA, Hosako M et al (2009) Taurine chloramine: a possible oxidant reservoir. Adv Exp Med Biol 643:451–461. https://doi.org/10.1007/978-0-387-75681-3_47
doi: 10.1007/978-0-387-75681-3_47
Björnsdottir H, Welin A, Michaëlsson E et al (2015) Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species. Free Radic Biol Med 89:1024–1035. https://doi.org/10.1016/j.freeradbiomed.2015.10.398
doi: 10.1016/j.freeradbiomed.2015.10.398
Galijasevic S, Abdulhamid I, Abu-Soud HM (2008) Melatonin is a potent inhibitor for myeloperoxidase. Biochemistry 47:2668–2677. https://doi.org/10.1021/bi702016q
doi: 10.1021/bi702016q
Pullar JM, Vissers MC, Winterbourn CC (2000) Living with a killer: the effects of hypochlorous acid on mammalian cells. IUBMB Life 50:259–266. https://doi.org/10.1080/713803731
doi: 10.1080/713803731
Banerjee J, Maitra D, Diamond MP, Abu-Soud HM (2012) Melatonin prevents hypochlorous acid-induced alterations in microtubule and chromosomal structure in metaphase-II mouse oocytes. J Pineal Res 53:122–128. https://doi.org/10.1111/j.1600-079X.2012.00977.x
doi: 10.1111/j.1600-079X.2012.00977.x
Molina-Carballo A, Palacios-López R, Jerez-Calero A et al (2022) Protective effect of melatonin administration against SARS-CoV-2 infection: a systematic review. Curr Issues Mol Biol 44:31–45. https://doi.org/10.3390/cimb44010003
doi: 10.3390/cimb44010003
Andersen LP, Gögenur I, Rosenberg J, Reiter RJ (2016) The safety of melatonin in humans. Clin Drug Investig 36:169–175. https://doi.org/10.1007/s40261-015-0368-5
doi: 10.1007/s40261-015-0368-5